# US 2015/0105385 A1 · Heterocyclic compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105385 A1
- Document ID: US20150105385A1
- Status: Published application
- Kind: A1
- Application number: 14/573,961
- Filed: 2014-12-17
- Published: 2015-04-16
- Earliest claimed: 2012-04-10
- Assignees: Infinity Pharmaceuticals, Inc.
- Applicants: Infinity Pharmaceuticals, Inc.
- Inventors: Alfredo C. CASTRO; Katrina CHAN; Catherine A. EVANS; Somarajannair JANARDANANNAIR; Andre LESCARBEAU; Liansheng LI; Tao LIU; Yi LIU; Pingda REN; Daniel A. SNYDER; Martin R. TREMBLAY
- Web page: https://patentgrep.com/patent/US20150105385A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 217/24: Oxygen atoms
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

## Claims

### Claim 1

A compound of Formula (I):
or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof, or a pharmaceutically acceptable form thereof, wherein
Cy is aryl or heteroaryl substituted by 0 or 1 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R5;
Wb5 is CR8, CHR8, or N;
R8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl or nitro;
B is hydrogen, alkyl, amino, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 occurrence(s) of R2;
each R2 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, or carbonate;
X is —(CH(R9))z—;
Y is —N(R9)—C(═O)—, —C(═O)—N(R9)—, —C(═O)—N(R9)—(CHR9)—, —N(R9)—S(═O)—, —S(═O)—N(R9)—, —S(═O)2—N(R9)—, —N(R9)—C(═O)—N(R9)—, or —N(R9)—S(═O)2—;
z is an integer of 1, 2, 3, or 4;
R3 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, aryl, heteroaryl, hydroxyl, or nitro;
each R5 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;
each R9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or heteroalkyl; or two adjacent occurrences of R9 together with the atoms to which they are attached form a 4- to 7-membered ring;
Wd is heterocyclyl, aryl, cycloalkyl, or heteroaryl, each of which is substituted with one or more R10, R11, R12, or R13, and
wherein R10, R11, R12, and R13 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
with the proviso that the compound is not:

### Claim 2 (depends on 1)

The compound of claim 1, having Formula (IIIb):
wherein R8 is hydrogen, alkyl, cyano, or halo; R9 is hydrogen or alkyl, and Y is —NH—C(O)—.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Cy is aryl substituted with 0 or 1 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R5.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Cy is aryl substituted with 0 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R5.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Cy is phenyl substituted with 1 occurrence of R3 and 0 occurrence of R5.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Cy is heteroaryl substituted with 0 or 1 occurrence of R3 and 0 occurrence of R5.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Cy is 5-membered heteroaryl substituted with 0 or 1 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R5.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Cy is thienyl substituted with 0 occurrence of R3 and 1 occurrence of R5.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Cy is isothiazolyl substituted with 0 occurrence of R3 and 1 occurrence of R5.

### Claim 10 (depends on 1)

The compound of claim 1, wherein Cy is a 6-membered heteroaryl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Wd is heteroaryl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein Wd is:
wherein X1, X2 and X3 are each independently C, CR13, or N; and
X4, X5 and X6 are each independently N, NH, CR13, S, or O.

### Claim 13 (depends on 1)

The compound of claim 1, having a structure of Formula (II):

### Claim 14 (depends on 13)

The compound of claim 13, having a structure of Formula (IIa) or Formula (IIb):

### Claim 15 (depends on 14)

The compound of claim 14, having a structure of Formula (IIIa) or Formula (IIIb):

### Claim 16 (depends on 1)

The compound of claim 1, having a structure of Formula (IIc):

### Claim 17 (depends on 16)

The compound of claim 16, having a structure of Formula (IIIc):

### Claim 18 (depends on 17)

The compound of claim 17, wherein R9 is alkyl, and Y is —NH—C(O)—.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen, halo, cyano, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, amino, acyl, heteroaryl, aryl, heterocyclyl, or cycloalkyl.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R3 is heteroaryl, aryl, alkyl, haloalkyl, OH, Cl, or F.

### Claim 21 (depends on 20)

The compound of claim 20, wherein R3 is heteroaryl, substituted or unsubstituted phenyl, CH3, CF3, OH, or Cl.

### Claim 22 (depends on 19)

The compound of claim 19, wherein R3 is CH3, OCH3, CF3, or halo.

### Claim 23 (depends on 19)

The compound of claim 19, wherein R3 is OCF3, CN, cyclopropyl, CH2OH, amino, formyl, heterocyclyl, alkenyl, or alkynyl.

### Claim 24 (depends on 1)

The compound of claim 1, wherein R8 is H, CH3, OCH3, CF3, CN, or halo.

### Claim 25 (depends on 1)

The compound of claim 1, having a structure of Formula (IVa) or Formula (VIb):

### Claim 26 (depends on 25)

The compound of claim 25, having a structure of Formula (Va) or Formula (Vb):

### Claim 27 (depends on 1)

The compound of claim 1, having a structure of Formula (VIa) or Formula (VIb):

### Claim 28 (depends on 27)

The compound of claim 27, wherein Wb5 is CR8.

### Claim 29 (depends on 27)

The compound of claim 27, wherein Wb5 is CH.

### Claim 30 (depends on 27)

The compound of claim 27, wherein R5 is selected from alkyl, cycloalkyl, halo, aryl, and heteroaryl.

### Claim 31 (depends on 27)

The compound of claim 27, wherein R5 is selected from methyl, chloro, and pyrazolo.

### Claim 32 (depends on 1)

The compound of claim 1, having a structure of Formula (VIc) or Formula (VId):

### Claim 33 (depends on 1)

The compound of claim 1, having a structure of Formula (VIe) or Formula (VIf):

### Claim 34 (depends on 33)

The compound of claim 33, wherein R5 is selected from alkyl, cycloalkyl, halo, aryl, and heteroaryl.

### Claim 35 (depends on 33)

The compound of claim 33, wherein R5 is selected from methyl, chloro, and pyrazolo.

### Claim 36 (depends on 1)

The compound of claim 1, wherein B is aryl, heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which is substituted with 0, 1, 2, or 3 occurrence(s) of R2.

### Claim 37 (depends on 1)

The compound of claim 1, wherein B is phenyl substituted with 0, 1, 2, or 3 occurrence(s) of R2.

### Claim 38 (depends on 1)

The compound of claim 1, wherein B is unsubstituted phenyl.

### Claim 39 (depends on 1)

The compound of claim 1, wherein B is phenyl substituted with 1 or 2 occurrence(s) of R2.

### Claim 40 (depends on 39)

The compound of claim 39, wherein R2 is halo or alkyl.

### Claim 41 (depends on 1)

The compound of claim 1, wherein B is methyl, isopropyl, or cyclopropyl.

### Claim 42 (depends on 1)

The compound of claim 1, wherein B is cyclohexyl or optionally substituted alkyl.

### Claim 43 (depends on 1)

The compound of claim 1, wherein Wd is:
wherein one of X1 and X2 is N and one of X1 and X2 is C or CR13; and X3 is CR13 or N.

### Claim 44 (depends on 1)

The compound of claim 1, wherein Wd is:

### Claim 45 (depends on 1)

The compound of claim 1, wherein Wd is:

### Claim 46 (depends on 1)

The compound of claim 1, wherein Wd is:

### Claim 47 (depends on 1)

The compound of claim 1, wherein Wd is:

### Claim 48 (depends on 1)

The compound of claim 1, wherein Wd is:

### Claim 49 (depends on 1)

The compound of claim 1, wherein Wd is

### Claim 50 (depends on 43, 44, 45, 47)

The compound of claim 43, 44, 45, 47, or 48, wherein R10 is NH2.

### Claim 51

A compound of Formula (XV):
or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof, or a pharmaceutically acceptable form thereof, wherein
Wb5 is N, CHR8, or CR8;
R8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;
Cy is aryl or heteroaryl substituted by 0 or 1 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R17;
R1 is -(L)-R1′;
L is a bond, —S—, —N(R15)—, —C(R15)2—, —C(═O)—, or —O—;
R1′ is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, substituted nitrogen, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
each R15 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or heteroalkyl;
R3 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, aryl, heteroaryl, hydroxyl, or nitro;
each R17 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
X is —(CH(R9))z—;
Y is —N(R9)—C(═O)—, —C(═O)—N(R9)—, —C(═O)—N(R9)—(CHR9)—, —N(R9)—S(═O)—, or —N(R9)—S(═O)2—;
z is an integer of 1, 2, 3, or 4;
each R9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or heteroalkyl;
Wd is heterocyclyl, aryl, cycloalkyl, or heteroaryl, each of which is substituted with one or more R10, R11, R12, or R13; and
wherein R10, R11, R12, and R13 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
with the proviso that said compound is not

### Claim 52 (depends on 51)

The compound of claim 51, wherein Cy is aryl substituted with 0 or 1 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R17.

### Claim 53 (depends on 51)

The compound of claim 51, wherein Cy is phenyl substituted with 0, 1, 2, or 3 occurrence(s) of R17.

### Claim 54 (depends on 51)

The compound of claim 51, wherein Cy is phenyl substituted with 1 occurrence of R3.

### Claim 55 (depends on 51)

The compound of claim 51, having a structure of Formula (XVI):

### Claim 56 (depends on 51)

The compound of claim 51, wherein R3 is halo, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocyclyl.

### Claim 57 (depends on 51)

The compound of claim 51, wherein R3 is alkyl or halo.

### Claim 58 (depends on 51)

The compound of claim 51, wherein L is —C(═O)—.

### Claim 59 (depends on 58)

The compound of claim 58, wherein R1′ is substituted alkyl, substituted nitrogen, or NR′R″, wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

### Claim 60 (depends on 59)

The compound of claim 59, wherein the cyclic moiety is a morpholino group.

### Claim 61 (depends on 1)

The compound of claim 1, wherein X is —CH2— or —CH(CH3)—.

### Claim 62 (depends on 61)

The compound of claim 61, wherein X is —CH(CH3)—.

### Claim 63 (depends on 62)

The compound of claim 62, wherein the CH carbon of the —CH(CH3)— moiety has an (S) stereochemical configuration.

### Claim 64 (depends on 62)

The compound of claim 62, wherein the CH carbon of the —CH(CH3)— moiety has an (R) stereochemical configuration.

### Claim 65 (depends on 1)

The compound of claim 1, wherein Y is —NH—C(O)—.

### Claim 66 (depends on 1)

The compound of claim 1, wherein —X—Y— is —CH2—N(CH3)—C(O)—.

### Claim 67 (depends on 1)

The compound of claim 1, wherein —X—Y— is (S)—CH(CH3)—NH—C(O)—.

### Claim 68 (depends on 1)

The compound of claim 1, wherein —X—Y— is (R)—CH(CH3)—NH—C(O)—.

### Claim 69 (depends on 1)

The compound of claim 1, wherein Wd is monocyclic heteroaryl.

### Claim 70 (depends on 69)

The compound of claim 69, wherein Wd is:
wherein X3 is CR13 or N.

### Claim 71 (depends on 70)

The compound of claim 70, wherein Wd is

### Claim 72 (depends on 71)

The compound of claim 71, wherein Wd is

### Claim 73 (depends on 64, 65)

The compound of any one of claim 64, 65, or 66, wherein R10 is NH2.

### Claim 74 (depends on 1)

The compound of claim 1, wherein Wd is a 5/6-bicyclic heteroaryl.

### Claim 75 (depends on 74)

The compound of claim 74, wherein Wd is:
wherein one of X1 and X2 is N and one of X1 and X2 is C.

### Claim 76 (depends on 75)

The compound of claim 75, wherein Wd is

### Claim 77 (depends on 75)

The compound of claim 75, wherein Wd is

### Claim 78 (depends on 75, 76)

The compound of any one of claim 75, 76, or 77, wherein R10 is NH2.

### Claim 79 (depends on 1)

The compound of claim 1, wherein Wd is a 6/6-bicyclic heteroaryl.

### Claim 80 (depends on 79)

The compound of claim 79, wherein Wd is
wherein one of X1 and X2 is N and one of X1 and X2 is CR13.

### Claim 81 (depends on 80)

The compound of claim 80, wherein R10 is NH2.

### Claim 82 (depends on 80)

The compound of claim 80, wherein Wd is

### Claim 83

A compound of Formula (X) or (XI):
or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof, or a pharmaceutically acceptable form thereof, wherein:
Wb5 is N, CHR8, or CR8;
R8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;
Cy is aryl or heteroaryl substituted by 0 or 1 occurrence of R3 and 0, 1, 2, or 3 occurrence(s) of R5;
R1 is -(L)-R1′;
L is a bond, —S—, —N(R15)—, —C(R15)2—, —C(═O)—, or —O—;
R1′ is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, substituted nitrogen, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
each R15 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or heteroalkyl;
R3 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, heteroaryl, aryl, hydroxyl, or nitro;
each R5 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety;
X is —(CH(R16))z—;
Y is N(R16)—C(═O)—, —C(═O)—N(R16)—, —C(═O)—N(R16)—(CHR16)—, —N(R16)—S(═O)—, or —N(R16)—S(═O)2—;
z is an integer of 1, 2, 3, or 4;
each R16 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroalkyl, aryl, halo, or heteroaryl; and
Wd is heterocyclyl, aryl, cycloalkyl, or heteroaryl, each of which is substituted with one or more R10, R11, R12, or R13; and
wherein R10, R11, R12, and R13 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

### Claim 84 (depends on 83)

The compound of claim 83, wherein Cy is a 6-membered ring.

### Claim 85 (depends on 83)

The compound of claim 83, wherein Cy is a phenyl ring.

### Claim 86 (depends on 83)

The compound of claim 83, wherein Wb5 is CH.

### Claim 87 (depends on 83)

The compound of claim 83, wherein Wd is:
wherein one of X1 and X2 is N and one of X1 and X2 is C or CR13; and X3 is CR13 or N.

### Claim 88 (depends on 87)

The compound of claim 87, wherein Wd is:

### Claim 89 (depends on 88)

The compound of claim 88, wherein Wd is:

### Claim 90 (depends on 87)

The compound of claim 87, wherein Wd is:

### Claim 91 (depends on 87)

The compound of claim 87, wherein Wd is:

### Claim 92 (depends on 87, 88, 90)

The compound of any one of claim 87, 88, 90, or 91, wherein R10 is NH2.

### Claim 93 (depends on 87)

The compound of claim 87, wherein Wd is

### Claim 94 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 95 (depends on 1)

A method of treating a PI3K mediated disorder in a subject, the method comprising administering a therapeutically effective amount of a compound of claim 1 to said subject.

### Claim 96 (depends on 95)

The method of claim 95, wherein the disorder is cancer, an inflammatory disease, or an auto-immune disease.

### Claim 97 (depends on 95)

The method of claim 95, wherein the PI3K mediated disorder is a PI3K-γ mediated disorder.

### Claim 98 (depends on 95)

The method of claim 95, wherein the PI3K mediated disorder is a PI3K-δ mediated disorder.
